Clinical Trial Update: The Role of the Amylin Analogue Cagrilintide in Bone Metabolism [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial investigating how the amylin analogue cagrilintide affects bone metabolism in obesity. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Cagrilintide (cagrilintide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Obesity | Phase 1 | Status: RECRUITING